It is now clear that the nephrology community has reached a consensus regarding the arteriovenous fistula (AVF)—it is the preferred dialysis access for hemodialysis patients. Indeed, an increasingly ...

In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...

This requires durable access to a blood vessel site where the dialysis machine can remove and return blood. Such access is created when a surgeon attaches a vein to an artery in the patient. The ...

Neither omega-3 fatty acids from fish nor aspirin prevented failure of arteriovenous fistulae (AVFs) in patients receiving hemodialysis, according to results of a new study published online January 3 ...

An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...

Humacyte, Inc. announced the results of its V007 Pivotal Phase 3 clinical trial for its acellular tissue engineered vessel (ATEV™), focused on arteriovenous access in patients with end-stage renal ...

Timmy Lee, MD, MSPH, is Associate Professor of Medicine in the Division of Nephrology and Staff Nephrologist at the Birmingham Veterans Affairs Medical Center. He is the Associate Director of ...

SALT LAKE CITY--(BUSINESS WIRE)--Alucent Biomedical Inc., a company dedicated to developing and commercializing its breakthrough AlucentNVS technology for the treatment of vascular disease, announced ...

The wealth or poverty of kidney disease patients' communities impacts the quality of care patients receive before starting dialysis, according to a study appearing in an upcoming issue of the Journal ...

BIRMINGHAM, Ala. – More than 600,000 people in the United States have end-stage kidney disease, and about 450,000 are kept alive through chronic hemodialysis to remove waste products from their blood.